MX378264B - Sistema para la entrega de polímeros líquidos para la administración prolongada de fármacos. - Google Patents

Sistema para la entrega de polímeros líquidos para la administración prolongada de fármacos.

Info

Publication number
MX378264B
MX378264B MX2018001499A MX2018001499A MX378264B MX 378264 B MX378264 B MX 378264B MX 2018001499 A MX2018001499 A MX 2018001499A MX 2018001499 A MX2018001499 A MX 2018001499A MX 378264 B MX378264 B MX 378264B
Authority
MX
Mexico
Prior art keywords
liquid polymer
drugs
delivery system
polymer delivery
extended administration
Prior art date
Application number
MX2018001499A
Other languages
English (en)
Other versions
MX2018001499A (es
Inventor
John Middleton
John Milton Downing
Vipin Saxena
Original Assignee
Tolmar International Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tolmar International Ltd filed Critical Tolmar International Ltd
Publication of MX2018001499A publication Critical patent/MX2018001499A/es
Publication of MX378264B publication Critical patent/MX378264B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/593—Polyesters, e.g. PLGA or polylactide-co-glycolide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Inorganic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Reproductive Health (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)

Abstract

Las composiciones farmacéuticas de polímero líquido con un poliéster líquido biodegradable que tiene un grupo terminal ácido carboxílico, un solvente biocompatible, y un agente farmacéutico activo, son útiles para ser administrados en el cuerpo para proveer una liberación prolongada ampliada del fármaco.
MX2018001499A 2015-08-03 2016-08-03 Sistema para la entrega de polímeros líquidos para la administración prolongada de fármacos. MX378264B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562200198P 2015-08-03 2015-08-03
US201662275407P 2016-01-06 2016-01-06
PCT/US2016/045334 WO2017024027A1 (en) 2015-08-03 2016-08-03 Liquid polymer delivery system for extended administration of drugs

Publications (2)

Publication Number Publication Date
MX2018001499A MX2018001499A (es) 2018-08-01
MX378264B true MX378264B (es) 2025-03-10

Family

ID=56684769

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018001499A MX378264B (es) 2015-08-03 2016-08-03 Sistema para la entrega de polímeros líquidos para la administración prolongada de fármacos.

Country Status (19)

Country Link
US (3) US10786515B2 (es)
EP (2) EP3331495B1 (es)
JP (1) JP6949820B2 (es)
KR (1) KR102696721B1 (es)
CN (1) CN107920988B (es)
AU (1) AU2016302252B2 (es)
BR (1) BR112018002414B1 (es)
CA (1) CA2994704A1 (es)
DK (1) DK3331495T3 (es)
EA (1) EA036951B1 (es)
ES (2) ES2975519T3 (es)
HR (1) HRP20201991T1 (es)
HU (1) HUE052832T2 (es)
IL (1) IL257221B (es)
MX (1) MX378264B (es)
PT (1) PT3331495T (es)
TW (1) TWI718168B (es)
WO (1) WO2017024027A1 (es)
ZA (1) ZA201800591B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2427383C2 (ru) 2006-01-18 2011-08-27 КьюПиЭс, ЭлЭлСи Фармацевтические композиции с повышенной стабильностью
US10786515B2 (en) 2015-08-03 2020-09-29 Tolmar International Limited Liquid polymer delivery system for extended administration of drugs
WO2019232280A1 (en) 2018-05-30 2019-12-05 Purdue Research Foundation Targeting anabolic drugs for accelerated fracture repair
KR102051808B1 (ko) 2018-07-23 2019-12-04 주식회사 종근당 테스토스테론 운데카노에이트를 포함하는 안정한 약제학적 조성물
CA3114061A1 (en) 2018-09-25 2020-04-02 Tolmar International, Ltd. Liquid polymer delivery system for extended administration of drugs
CN109966557A (zh) * 2018-12-05 2019-07-05 博志生物科技有限公司 局部缓释Abaloparatide或相关多肽的GelMA水凝胶的制备方法及应用
PT4302773T (pt) 2019-09-30 2024-12-10 Tolmar International Ltd Composições e sistemas de polímeros líquidos para administração prolongada de péptidos como substâncias farmacêuticas ativas
CN110946826B (zh) * 2019-12-12 2022-02-22 烟台大学 一种利奥西呱口服制剂及其制备方法
WO2022069996A1 (en) 2020-09-30 2022-04-07 Tolmar International Limited Biodegradable polymer and solvent compositions and systems for extended storage and delivery of active pharmaceutical ingredients
WO2024117740A1 (ko) * 2022-11-28 2024-06-06 동국제약 주식회사 인-시튜 임플란트를 형성할 수 있는 서방형 약학 조성물 및 이의 제조방법
CN119630413A (zh) * 2022-12-23 2025-03-14 长春金赛药业有限责任公司 一种GnRH拮抗剂可注射组合物及其制备方法和应用
WO2024168022A2 (en) * 2023-02-10 2024-08-15 Tolmar, Inc. Degarelix polymeric formulations
KR20250142363A (ko) * 2023-02-10 2025-09-30 톨마 인터내셔날 리미티드 데가렐릭스 유기 용매 제형

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4938763B1 (en) 1988-10-03 1995-07-04 Atrix Lab Inc Biodegradable in-situ forming implants and method of producing the same
US6197320B1 (en) * 1994-03-11 2001-03-06 Shalaby W. Shalaby Absorbable E-caprolactone polymers and medical devices
US5668288A (en) 1996-04-16 1997-09-16 Depuy Orthopaedics, Inc. Polyester ionomers for implant fabrication
US6458373B1 (en) 1997-01-07 2002-10-01 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
US6201072B1 (en) 1997-10-03 2001-03-13 Macromed, Inc. Biodegradable low molecular weight triblock poly(lactide-co- glycolide) polyethylene glycol copolymers having reverse thermal gelation properties
US6565874B1 (en) * 1998-10-28 2003-05-20 Atrix Laboratories Polymeric delivery formulations of leuprolide with improved efficacy
US8470359B2 (en) 2000-11-13 2013-06-25 Qlt Usa, Inc. Sustained release polymer
AU2002226000A1 (en) 2000-11-13 2002-05-21 Atrix Laboratories, Inc. Injectable sustained release delivery system with loperamide
EP1334990A1 (en) 2002-02-06 2003-08-13 Polyganics B.V. DL-Lactide-epsilon-caprolactone copolymers
US20120225033A1 (en) 2010-11-24 2012-09-06 Durect Corporation Biodegradable Drug Delivery Composition
DK1635875T3 (da) 2003-06-26 2009-01-12 Psivida Inc In-situ-geldannende lægemiddeladministrationssystem
JP2008524235A (ja) * 2004-12-15 2008-07-10 キューエルティー ユーエスエー，インコーポレイテッド． オクトレオチド化合物の徐放性送達処方物
PL2985026T3 (pl) 2005-04-15 2023-02-20 Clarus Therapeutics, Inc. Farmaceutyczne systemy dostarczania leków hydrofobowych i zawierające je kompozycje
WO2007019439A2 (en) 2005-08-04 2007-02-15 Angiotech International Ag Block copolymer compositions and uses thereof
US20070299043A1 (en) 2005-10-03 2007-12-27 Hunter William L Anti-scarring drug combinations and use thereof
RU2427383C2 (ru) * 2006-01-18 2011-08-27 КьюПиЭс, ЭлЭлСи Фармацевтические композиции с повышенной стабильностью
US7740877B2 (en) 2006-04-07 2010-06-22 University Of Utah Research Foundation Aliphatically modified biodegradable block copolymers as thermogelling polymers
WO2009060473A2 (en) * 2007-11-06 2009-05-14 Panacea Biotec Limited Injectable compositions, processes and uses thereof
US20090181068A1 (en) 2008-01-14 2009-07-16 Dunn Richard L Low Viscosity Liquid Polymeric Delivery System
US8946277B2 (en) * 2008-04-18 2015-02-03 Warsaw Orthopedic, Inc. Clonidine formulations in a biodegradable polymer carrier
WO2010018159A1 (en) 2008-08-12 2010-02-18 Novartis Ag Pharmaceutical compositions
US8541360B2 (en) 2008-11-19 2013-09-24 Ben Venue Laboratories, Inc. Parenteral formulations comprising sugar-based esters and ethers
CA2749997A1 (en) * 2009-01-23 2010-07-29 Surmodics Pharmaceuticals, Inc. Polymer mixtures comprising polymers having different non-repeating units and methods for making and using same
MY159098A (en) 2009-04-24 2016-12-15 Iceutica Pty Ltd Production of encapsulated nanoparticles at high volume fractions
GB2513267B (en) * 2010-06-08 2015-03-18 Rb Pharmaceuticals Ltd Injectable flowable composition comprising buprenorphine
PL2859887T3 (pl) 2010-07-09 2017-10-31 Innocore Tech B V Biodegradowalne segmentowane kopolimery wieloblokowe z rozdziałem faz oraz uwalnianie biologicznie czynnych polipeptydów
CN103228444A (zh) * 2010-11-04 2013-07-31 新日铁住金化学株式会社 带有硬涂层的聚碳酸酯
US20140309202A1 (en) 2010-11-30 2014-10-16 Lipocine Inc. High-strength testosterone undecanoate compositions
AU2012237260A1 (en) 2011-03-31 2013-11-14 Ingell Technologies Holding B.V. Biodegradable compositions suitable for controlled release
PL2717914T3 (pl) * 2011-06-10 2020-05-18 Ramscor, Inc. Formulacje o przedłużonym uwalnianiu do dostarczania białek do oka i sposoby ich wytwarzania
CN103998069A (zh) * 2011-10-17 2014-08-20 聚合-医药有限公司 可吸收的原位凝胶形成系统、其制备方法及用途
DK3137532T3 (da) 2014-05-01 2021-08-02 Ingell Tech Holding B V Flydende triblok-copolymer
KR101686986B1 (ko) 2014-07-28 2016-12-16 에스케이케미칼주식회사 류프로라이드를 포함하는 속효성과 지속성을 동시에 갖는 약제학적 조성물
US10786515B2 (en) 2015-08-03 2020-09-29 Tolmar International Limited Liquid polymer delivery system for extended administration of drugs
US11752099B2 (en) 2017-03-27 2023-09-12 W. L. Gore & Associates, Inc. Injectable and biodegradable polymer formulations for controlled release of bioactive agents

Also Published As

Publication number Publication date
EP3331495A1 (en) 2018-06-13
US10786515B2 (en) 2020-09-29
IL257221B (en) 2022-01-01
US12447158B2 (en) 2025-10-21
US20180214459A1 (en) 2018-08-02
ZA201800591B (en) 2021-07-28
MX2018001499A (es) 2018-08-01
EP3331495B1 (en) 2020-11-04
JP2018522906A (ja) 2018-08-16
US11779589B2 (en) 2023-10-10
ES2975519T3 (es) 2024-07-08
DK3331495T3 (da) 2020-12-14
PT3331495T (pt) 2020-12-07
IL257221A (en) 2018-03-29
BR112018002414A2 (pt) 2018-09-18
TW201717960A (zh) 2017-06-01
EA036951B1 (ru) 2021-01-19
TWI718168B (zh) 2021-02-11
NZ739674A (en) 2024-10-25
EP3804698A1 (en) 2021-04-14
CA2994704A1 (en) 2017-02-09
KR102696721B1 (ko) 2024-08-19
EA201890436A1 (ru) 2018-09-28
US20240066039A1 (en) 2024-02-29
BR112018002414B1 (pt) 2023-11-21
ES2836805T3 (es) 2021-06-28
AU2016302252A1 (en) 2018-02-22
HK1255638A1 (en) 2019-08-23
KR20180030413A (ko) 2018-03-22
WO2017024027A1 (en) 2017-02-09
HRP20201991T1 (hr) 2021-02-05
AU2016302252B2 (en) 2022-01-20
US20210060036A1 (en) 2021-03-04
CN107920988B (zh) 2021-08-17
JP6949820B2 (ja) 2021-10-13
EP3804698B1 (en) 2024-01-31
HUE052832T2 (hu) 2021-05-28
CN107920988A (zh) 2018-04-17

Similar Documents

Publication Publication Date Title
MX378264B (es) Sistema para la entrega de polímeros líquidos para la administración prolongada de fármacos.
WO2017091749A8 (en) Shape changing drug delivery devices and methods
NZ746573A (en) Compositions comprising electrohydrodynamically obtained fibres for administration of specific dosages of an active substance to skin or mucosa
WO2012035429A3 (en) Remotely controlled drug delivery systems
MX352907B (es) Composiciones de un poliortoéster y un solvente aprótico.
EP4512394A3 (en) Dosage forms and use thereof
MX2015011393A (es) Poli(beta-amino esteres) modificados para suministro de farmaco.
MX2017006653A (es) Metodos para modular los niveles de fármaco en plasma mediante el uso de eritrohidroxibupropión.
MX2019003804A (es) Dispositivos implantables para suministro de medicamento con liberacion de descarga reducida.
WO2011112229A3 (en) Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
EA033537B1 (ru) Инъекционная композиция с контролируемым высвобождением, содержащая жидкий носитель с высокой вязкостью
WO2015095624A3 (en) Drug mixing and delivery system and method
MD20160079A2 (ro) Sistem de livrare a medicamentului
WO2013036309A3 (en) Sustained release formulations for delivery of proteins to the eye and methods of preparing same
AR116501A1 (es) Sistema de suministro de polímero líquido para administración extendida de drogas
WO2011112996A3 (en) Injectable drug delivery system
MX2016001607A (es) Microesferas de entecavir y composicion farmaceutica para administracion parenteral que contiene las mismas.
MX2016015261A (es) Dispersion solida de allisartan isoproxilo y su composicion.
PE20160850A1 (es) Sistema multiparticulado para administrar drogas
CR20140358A (es) Sistema para la administración de fármacos
PE20160534A1 (es) Sistema de administracion intrauterina
EP3801703A4 (en) Tissue integrated drug delivery system
WO2016036823A3 (en) Self-assembling drug delivery vehicles with ionically cross-linked drugs
MX364652B (es) Formulacion farmaceutica que comprende ciclesonida.
WO2014165513A3 (en) Ethylsulfonated hyaluronic acid biopolymers and methods of use thereof